Trade Novavax NVAX

Novavax live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2025 Jun 25, 00:00

Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication

Novavax Inc
Webhose 2025 Jun 23, 15:00

Cidara soars on phase IIb CD-388 flu data | BioWorld

Novavax Inc
Webhose 2025 Jun 23, 05:00

Novavax jumps 15% on COVID shot nod, among 14 FDA approvals in May | BioWorld

Novavax Inc
Webhose 2025 Jun 17, 16:44

Novavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?

Novavax Inc
Webhose 2025 Jun 17, 12:35

Novavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at Citigroup

Novavax Inc
Webhose 2025 Jun 11, 07:22

Novavax: CIC And Flu Vaccine Candidates Induce Immune Responses Similar To Licensed Comparators

Novavax Inc
Webhose 2025 Jun 03, 07:37

Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Nuveen Asset Management LLC

Novavax Inc
Webhose 2025 May 30, 17:45

Novavax call volume above normal and directionally bullish | Markets Insider

Novavax Inc
Webhose 2025 May 28, 21:05

Novavax (NASDAQ:NVAX) Trading Down 5.4% - Time to Sell?

Novavax Inc
Webhose 2025 May 28, 07:24

Deutsche Bank AG Increases Stock Holdings in Novavax, Inc. (NASDAQ:NVAX)

Novavax Inc
Webhose 2025 May 27, 08:27

Two Sigma Advisers LP Sells 1,219,700 Shares of Novavax, Inc. (NASDAQ:NVAX)

Novavax Inc
Webhose 2025 May 27, 07:38

Millennium Management LLC Reduces Stake in Novavax, Inc. (NASDAQ:NVAX)

Novavax Inc

Novavax news

Latest news

Show more

Info

Spread

0.08

Spread (%)

1.2500 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Market open

Thursday

13:31 - 19:59

Monday

13:31-19:59

Tuesday

13:31-19:59

Wednesday

13:31-19:59

Friday

13:31-19:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1049565632

Shares Outstanding

161970000

Earnings Date (Next)

2019-05-10

Div Yield

2019-05-10

Ex-Dividend Date 

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

2.75

Learn more about this instrument

Novavax Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Related Instruments

Asset
Sell
Buy
Change (%)
view_all_instruments

Latest Education Articles

Show more
Trustpilot